IL110011A - Pharmacological preparations for the treatment of schizophrenia - Google Patents

Pharmacological preparations for the treatment of schizophrenia

Info

Publication number
IL110011A
IL110011A IL11001194A IL11001194A IL110011A IL 110011 A IL110011 A IL 110011A IL 11001194 A IL11001194 A IL 11001194A IL 11001194 A IL11001194 A IL 11001194A IL 110011 A IL110011 A IL 110011A
Authority
IL
Israel
Prior art keywords
immunosuppressive agent
treatment
schizophrenia
azathioprine
prednisone
Prior art date
Application number
IL11001194A
Other languages
English (en)
Hebrew (he)
Other versions
IL110011A0 (en
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11001194A priority Critical patent/IL110011A/en
Publication of IL110011A0 publication Critical patent/IL110011A0/xx
Priority to US08/750,169 priority patent/US5912250A/en
Priority to AT95924223T priority patent/ATE216891T1/de
Priority to JP8501635A priority patent/JPH10501257A/ja
Priority to ES95924223T priority patent/ES2176331T3/es
Priority to DE69526584T priority patent/DE69526584T2/de
Priority to EP95924223A priority patent/EP0772442B1/en
Priority to BR9508021-0A priority patent/BR9508021A/pt
Priority to CA002192822A priority patent/CA2192822C/en
Priority to PCT/EP1995/002289 priority patent/WO1995034306A1/en
Priority to AU28819/95A priority patent/AU704355B2/en
Publication of IL110011A publication Critical patent/IL110011A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11001194A 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia IL110011A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia
AU28819/95A AU704355B2 (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia
ES95924223T ES2176331T3 (es) 1994-06-13 1995-06-13 Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.
AT95924223T ATE216891T1 (de) 1994-06-13 1995-06-13 Verwendung von immunosuppressiva zur behandlung der schizophrenie
JP8501635A JPH10501257A (ja) 1994-06-13 1995-06-13 精神分裂病の処置のための免疫抑制剤の使用
US08/750,169 US5912250A (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia
DE69526584T DE69526584T2 (de) 1994-06-13 1995-06-13 Verwendung von immunosuppressiva zur behandlung der schizophrenie
EP95924223A EP0772442B1 (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia
BR9508021-0A BR9508021A (pt) 1994-06-13 1995-06-13 Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
CA002192822A CA2192822C (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia
PCT/EP1995/002289 WO1995034306A1 (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
IL110011A0 IL110011A0 (en) 1994-10-07
IL110011A true IL110011A (en) 2004-09-27

Family

ID=11066236

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia

Country Status (11)

Country Link
US (1) US5912250A (pt)
EP (1) EP0772442B1 (pt)
JP (1) JPH10501257A (pt)
AT (1) ATE216891T1 (pt)
AU (1) AU704355B2 (pt)
BR (1) BR9508021A (pt)
CA (1) CA2192822C (pt)
DE (1) DE69526584T2 (pt)
ES (1) ES2176331T3 (pt)
IL (1) IL110011A (pt)
WO (1) WO1995034306A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020273A1 (en) * 1997-10-17 1999-04-29 The Rockefeller University Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
US7112566B1 (en) * 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
ES2326078T3 (es) 2002-08-22 2009-09-30 Dainippon Sumitomo Pharma Co., Ltd. Medicamento destinado al sindrome de la disfuncion de integracion.
AU2004249621B2 (en) 2003-06-23 2009-08-06 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
JP4847320B2 (ja) 2004-02-20 2011-12-28 大日本住友製薬株式会社 統合失調症の記憶・学習機能障害治療薬のｉｎｖｉｖｏスクリーニング方法
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
IL110011A0 (en) 1994-10-07
BR9508021A (pt) 2004-04-20
DE69526584T2 (de) 2002-11-14
AU704355B2 (en) 1999-04-22
US5912250A (en) 1999-06-15
AU2881995A (en) 1996-01-05
CA2192822C (en) 2007-04-03
DE69526584D1 (de) 2002-06-06
EP0772442A1 (en) 1997-05-14
JPH10501257A (ja) 1998-02-03
EP0772442B1 (en) 2002-05-02
WO1995034306A1 (en) 1995-12-21
CA2192822A1 (en) 1995-12-21
ES2176331T3 (es) 2002-12-01
ATE216891T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
Melzer et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society
Tormoehlen et al. Thymoma, myasthenia gravis, and other paraneoplastic syndromes
Vasquez Sirolimus: a new agent for prevention of renal allograft rejection
Min et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial
Mendenopoulos et al. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation
Diener et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol
BR112019011208A2 (pt) combinação farmacêutica, composição farmacêutica, e, kit de partes.
EP0772442B1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
AU2019479685A1 (en) TACI-Fc fusion protein and use thereof
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
Evoli et al. A practical guide to the recognition and management of myasthenia gravis
ES2965454T3 (es) Protocolo mejorado para el tratamiento de la nefritis lúpica
CN105770891A (zh) TACI-Ig 融合蛋白如ATACICEPT 用于制备治疗红斑狼疮的药物的用途
Delic Inpatient management of GHB/GBL withdrawal
Jalenques et al. Weight gain as a predictor of long term clozapine efficacy
Rabben et al. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain
US12023315B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
Karanikolas et al. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis.
Miranda et al. A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis
EP3654989B1 (en) Use of cladribine for treating autoimmune neuromuscular disease
KR20230050363A (ko) 질환의 치료에 있어서 btk 저해제의 용도
WO2001074339A2 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
Ponticelli et al. The pharmacology of old and new agents for specific therapy of primary glomerular diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees